ENDLOS-TURBO CALL - CUREVAC Share Price

DE000DQ0Y2K1

Market Closed - Boerse Frankfurt Warrants 20:35:03 17/05/2024 BST
1.31 ^EUR	-2.24%

Current month	+151.92%
1 month	+133.93%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart CUREVAC N.V.

Latest news about CUREVAC N.V.

CUREVAC : A missed opportunity	05-02
UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating	04-26	MT
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza Development in Collaboration with GSK	04-25	AQ
Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4	04-25	MT

More news

Quotes 5-day view

Date	Price	Change
17/05/24	1.31	-2.24%
16/05/24	1.34	+20.72%
15/05/24	1.11	+13.27%
14/05/24	0.98	+10.11%
13/05/24	0.89	+4.71%

Real-time Boerse Frankfurt Warrants

Last update May 17, 2024 at 08:35 pm

More quotes

Static data

Product type	Knock-Out without Stop Loss
Buy / Sell	CALL
Underlying	CUREVAC N.V.
Issuer	DZ BANK
WKN	DQ0Y2K
ISIN	DE000DQ0Y2K1
Date issued	27/02/2024
Strike	2.023 $
Maturity	Unlimited
Parity	1 : 1
Emission price	1.22 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	1.79 €
Lowest since issue	0.23 €

Company Profile

CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve peopleâs lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.

Sector

More about the company

Ratings for CureVac N.V.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Consensus: CureVac N.V.

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.21 EUR

Average target price

9.01 EUR

Spread / Average Target

+180.68%

Consensus